Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1602)	6/4/2003 3:19:58 AM
From: Icebrg	Respond to of 3044

Tuck >>Feuerstein did a reasonably balanced piece on all this 6 months ago:>> From that article. Even if the Angiomax study is positive, Millennium Pharmaceuticals believes it will have a negligible impact on sales of its IIb/IIIa inhibitor, Integrilin, according to John Maraganore, senior vice president for strategic product development. "Recent treatment guidelines released by the American College of Cardiology make the Replace II outcome a non-event," says Maraganore. That's because a growing number of patients who are rushed to the hospital with chest pain or a heart attack are being put on IIb/IIIa inhibitors like Integrilin as soon as they're admitted. Therefore, cardiologists are unlikely to take them off the drug before starting angioplasty or installing a stent, he adds. The only patient population where Angiomax might steal market share is in patients having elective procedures, Maraganore concedes, but he claims that this is a small part of Integrilin's overall sales. Millennium is forecasting 2002 Integrilin sales of $300 million, or about 30% growth last year. The company will not give 2003 sales guidance until January. Well, Maraganore should know. He is the inventor of Angiomax. (At Biogen during an earlier phase of his life). He has since left Millennium to become President and CEO of Alnylam Pharmaceuticals. Must have become too difficult to constantly having to issue negative opinions on Angiomax. (Well, his departure didn't matter too much, as it made it possible to promote Kailian). Erik